Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Claes

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 17, 2008
Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degenerationKoen Poesen, Diether Lambrechts, Philip Van Damme, et al.
Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
JCO Precision Oncology|February 1, 2022
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor TherapyJoan Maurel, Vicente Alonso, Pilar Escudero, et al.
Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Human Molecular Genetics|May 21, 2011
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association ConsortiumAnnegien Broeks, Marjanka K Schmidt, Mark E Sherman, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 17, 2008
Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degenerationKoen Poesen, Diether Lambrechts, Philip Van Damme, et al.
Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
JCO Precision Oncology|February 1, 2022
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor TherapyJoan Maurel, Vicente Alonso, Pilar Escudero, et al.
Oncotarget|September 3, 2015
BRAF mutation testing with a rapid, fully integrated molecular diagnostics systemFilip Janku, Bart Claes, Helen J Huang, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Human Molecular Genetics|May 21, 2011
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association ConsortiumAnnegien Broeks, Marjanka K Schmidt, Mark E Sherman, et al.
Pageof 2